9 completed, 4 terminated, 1 withdrawn. 10 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Terminated 2, Withdrawn 1 |
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 3 | Terminated 3 |
Follow rilotumumab: new trials by email Literature Review of rilotumumab trials Research Report on rilotumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Docetaxel, Durvalumab, Erlotinib Hydrochloride - Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Completed | SWOG Cancer Research Network | 1864 | 2014-07-08 | 2023-06-01 | |
| A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Rilotumumab, Placebo, Cisplatin - Gastric Cancer | Phase 3 | Terminated | Amgen | 34 | 2014-07-01 | 2016-04-04 |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Rilotumumab - MET Positive, Recurrent Squamous Cell Lung Carcinoma | Phase 2 / Phase 3 | Terminated | SWOG Cancer Research Network | 9 | 2014-06-16 | 2020-03-19 |
| Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ Rilotumumab - Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer | Phase 1 | Completed | Amgen | 21 | 2012-11-01 | 2016-02-29 |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma Rilotumumab, Placebo, Epirubicin - Gastric Cancer | Phase 3 | Terminated | Amgen | 609 | 2012-10-01 | 2016-02-09 |
| AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer AMG 102 and erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Ahmad Tarhini | 49 | 2011-08-01 | 2017-06-22 |
| MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma Oxaliplatin, Folinic Acid, 5-fluoro-uracil - Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach | Phase 2 | Completed | UNICANCER | 162 | 2011-01-01 | 2020-11-17 |
| Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Rilotumumab - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2010-10-01 | 2017-09-07 |
| AMG 102 and Avastin for Recurrent Malignant Glioma AMG 102, Avastin - Glioblastoma Multiforme, Gliosarcoma | Phase 2 | Completed | Katy Peters | 36 | 2010-08-01 | 2015-12-10 |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma rilotumumab, cisplatin, pemetrexed disodium - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-04-01 | 2013-08-02 | |
| AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer Capecitabine, Epirubicin, AMG 102 - Esophagogastric Junction Adenocarcinoma, Gastric Cancer | Phase 1 / Phase 2 | Completed | Amgen | 130 | 2009-02-01 | 2013-12-05 |
| QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer AMG 479, Etoposide, Placebo - Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 213 | 2008-12-02 | 2024-08-23 |
| AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer AMG 102, Mitoxantrone, Placebo - Cancer, Castrate-Resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Amgen | 162 | 2008-11-01 | 2014-03-10 |
| Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) Panitumumab, Ganitumab, Rilotumumab - Colon Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Completed | NantBioScience, Inc. | 177 | 2008-10-27 | 2024-08-07 |
Stomach Neoplasms (5) · Esophageal Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Lung Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1)
Amgen (5) · SWOG Cancer Research Network (2) · Ahmad Tarhini (1) · Gynecologic Oncology Group (1) · Katy Peters (1) · NantBioScience, Inc. (1) · NantCell, Inc. (1) · National Cancer Institute (NCI) (1) · UNICANCER (1)
United States (6) · Canada (2) · France (2) · Japan (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1)
Vassiliki Papadimitrakopoulou (2) · Ahmad Tarhini, MD (1)
PMID 25712685, PMID 26049686, PMID 26410619, PMID 28958504, PMID 28973403, PMID 29666296, PMID 33125909, PMID 39111731
U10CA180888 (2), 2009 (1), U10CA021115 (1), U10CA027469 (1), U10CA180868 (1)